Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Department of Psychiatry and 2Department of Neurology, University of California San Francisco School of Medicine, San Francisco, CA, USA
Список исп. литературыСкрыть список 1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association, 2013. 2. American Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. Darien: American Academy of Sleep Medicine, 2014. 3. Ohayon MM, Reynolds CF. Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the Intern-tional Classification of Sleep Disorders (ICSD). Sleep Med 2009;10:952-60. 4. Roth T, Coulouvrat C, Hajak G et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Clas-sification of Diseases and Related Health Problems, tenth revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders. Biol Psychiatry 2011;69:592-600. 5. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97-111. 6. Morin CM, LeBlanc M, Bélanger L et al. Prevalence of insomnia and its treatment in Canada. Can J Psychiatry 2011;56:540-8. 7. Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and com-plementary and alternative medicine: analysis of the 2002 National Health Interview Survey data. Arch Intern Med 2006;166:1775-82. 8. Roth T, Jaeger S, Jin R et al. Sleep problems, comorbid mental disorders, and role functioning in the National Comorbidity Survey Replication. Biol Psychiatry 2006;60:1364-71. 9. Sarsour K, Morin CM, Foley K et al. Association of insomnia severity and comorbid medical and psychiatric disorders in a health plan-based sample: insomnia severity and comorbidities. Sleep Med 2010;11:69-74. 10. Budhiraja R, Roth T, Hudgel DW et al. Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep 2011;34:859-67. 11. Baglioni C, Battagliese G, Feige B et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord 2011;135:10-9. 12. Breslau N, Roth T, Rosenthal L et al. Sleep disturbance and psychiatric dis-orders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-8. 13. Drake CL, Pillai V, Roth T. Stress and sleep reactivity: a prospective investigation of the stress diathesis model of insomnia. Sleep 2014;37:1295-304. 14. Johnson EO, Chilcoat HD, Breslau N. Trouble sleeping and anxiety/depression in childhood. Psychiatry Res 2000;94:93-102. 15. Johnson EO, Roth T, Breslau N. The association of insomnia with anxiety disorders and depression: exploration of the direction of risk. J Psychiatr Res 2006;40:700-8. 16. Pigeon WR, Pinquart M, Conner K. Meta-analysis of sleep disturbance and suicidal thoughts and behaviors. J Clin Psychiatry 2012;73:e1160-7. 17. Vgontzas AN, Liao D, Bixler EO et al. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep 2009;32:491-7. 18. Fernandez-Mendoza J, Vgontzas AN, Liao D et al. Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort. Hypertension 2012;60:929-35. 19. Parthasarathy S, Vasquez MM, Halonen M et al. Persistent insomnia is associated with mortality risk. Am J Med 2015;128:268-75. 20. Kessler RC, Berglund PA, Coulouvrat C et al. Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia Survey. Sleep 2012;35:825-34. 21. Koski K, Luukinen H, Laippala P et al. Risk factors for major injurious falls among the home dwelling elderly by functional abilities. A prospective population-based study. Gerontology 1998;44:232-8. 22. Avidan AY, Fries BE, James ML et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 2005;53:955-62. 23. Stone KL, Blackwell TL, Ancoli-Israel S et al. Sleep disturbances and risk of falls in older community-dwelling men: the outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study. J Am Geriatr Soc 2014;62:299-305. 24. National Institutes of Health. National Institutes of Health state of the science conference statement on manifestations and management of chronic insomnia in adults, June 13-15, 2005. Sleep 2005;28:1049-57. 25. Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev 2009;13:265-74. 26. Sateia MJ, Buysse DJ, Krystal AD et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 2017;13:307-49. 27. Miller CB, Espie CA, Epstein DR et al. The evidence base of sleep restriction therapy for treating insomnia disorder. Sleep Med Rev 2014;18:415-24. 28. Morin CM, Bootzin RR, Buysse DJ et al. Psychological and behavioral treatment of insomnia: update of the recent evidence. Sleep 2006;29:1398-414. 29. Matteson-Rusby SE, Pigeon WR, Gehrman P et al. Why treat insomnia? Prim Care Companion J Clin Psychiatry 2010;12:PCC.08r00743. 30. Edinger JD, Wyatt JK, Stepanski EJ et al. Testing the reliability and validity of DSM-IV-TR and ICSD-2 insomnia diagnoses. Arch Gen Psychiatry 2011;68:992-1002. 31. Vgontzas AN, Liao D, Pejovic S et al. Insomnia with objective short sleep duration is associated with type 2 diabetes: a population-based study. Diabetes Care 2009;32:1980-5. 32. Fernandez-Mendoza J, Calhoun S, Bixler EO et al. Insomnia with objective short sleep duration is associated with deficits in neuropsychological performance: a general population study. Sleep 2010;33:459-65. 33. Johnson EO. Epidemiology of insomnia: from adolescence to old age. Sleep Med Clin 2006;1:305-17. 34. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 1985;42:225-32. 35. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007;3(Suppl.5):S7-10. 36. Leger D, Guilleminault C, Dreyfus JP et al. Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res 2000;9:35-42. 37. Morin CM, Bélanger L, LeBlanc M et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med 2009;169:447-53. 38. Beaulieu-Bonneau S, LeBlanc M, Mérette C et al. Family history of insomnia in a population-based sample. Sleep 2007;30:1739-45. 39. Kim K, Uchiyama M, Okawa M et al. An epidemiological study of insomnia among the Japanese general population. Sleep 2000;23:41-7. 40. Ohayon M. Epidemiological study on insomnia in the general population. Sleep 1996;19(Suppl. 3):S7-15. 41. Bixler EO, Kales A, Soldatos CR et al. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry 1979;136:1257-62. 42. Maggi S, Langlois JA, Minicuci N et al. Sleep complaints in community-dwelling older persons: prevalence, associated factors, and reported caus-es. J Am Geriatr Soc 1998;46:161-8. 43. Foley DJ, Monjan AA, Brown SL et al. Sleep complaints among elderly per-sons: an epidemiologic study of three communities. Sleep 1995;18:425-32. 44. Weissman MM, Bland RC, Canino GJ et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276:293-9. 45. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-84. 46. Henderson S, Jorm AF, Scott LR et al. Insomnia in the elderly: its prevalence and correlates in the general population. Med J Aust 1995;162:22-4. 47. Tamura H, Nishida T, Tsuji A et al. Association between excessive use of mobile phone and insomnia and depression among Japanese adoles-cents. Int J Environ Res Publ Health 2017;14:701. 48. Spielman AJ, Caruso LS, Glovinsky PB. A behavioral-perspective on insomnia treatment. Psychiatr Clin North Am 1987;10:541-53. 49. Brainard GC, Hanifin JP, Greeson JM et al. Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci 2001;21:6405-12. 50. Yang C-M, Spielman AJ, Glovinsky P. Nonpharmacologic strategies in the management of insomnia. Psychiatr Clin North Am 2006;29:895-919. 51. Ebben MR, Spielman AJ. Non-pharmacological treatments for insomnia. J Behav Med 2009;32:244-54. 52. Gislason T, Almqvist M. Somatic diseases and sleep complaints. An epidemiological study of 3,201 Swedish men. Acta Med Scand 1987;221:475-81. 53. Stoschitzky K, Sakotnik A, Lercher P et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 1999;55:111-5. 54. Schutte-Rodin S, Broch L, Buysse D et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008;4:487-504. 55. Theorell-Haglow J, Miller CB, Bartlett DJ et al. Gender differences in obstructive sleep apnoea, insomnia and restless legs syndrome in adults– What do we know? A clinical update. Sleep Med Rev 2018;38:28-38. 56. Valipour A, Lothaller H, Rauscher H et al. Gender-related differences in symptoms of patients with suspected breathing disorders in sleep: a clini-cal population study using the sleep disorders questionnaire. Sleep 2007;30:312-9. 57. Morgenthaler T, Alessi C, Friedman L et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep 2007;30:519-29. 58. Hyde M, O’Driscoll DM, Binette S et al. Validation of actigraphy for deter-mining sleep and wake in children with sleep disordered breathing. J Sleep Res 2007;16:213-6. 59. Hedner J, Pillar G, Pittman SD et al. A novel adaptive wrist actigraphy algorithm for sleep-wake assessment in sleep apnea patients. Sleep 2004;27:1560-6. 60. Martin JL, Hakim AD. Wrist actigraphy. Chest 2011;139:1514-27. 61. Gruwez A, Libert W, Ameye L et al. Reliability of commercially available sleep and activity trackers with manual switch-to-sleep mode activation in free-living healthy individuals. Int J Med Inform 2017;102:87-92. 62. Ko PR, Kientz JA, Choe EK et al. Consumer sleep technologies: a review of the landscape. J Clin Sleep Med 2015;11:1455-61. 63. Krystal AD, Edinger JD, Wohlgemuth WK et al. NREM sleep EEG frequency spectral correlates of sleep complaints in primary insomnia subtypes. Sleep 2002;25:630-40. 64. Johns MW. A new method for measuring daytime sleepiness: the Ep-worth Sleepiness Scale. Sleep 1991;14:540-5. 65. Morin CM, Belleville G, Bélanger L et al. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep 2011;34:601-8. 66. Morin CM, Vallières A, Ivers H. Dysfunctional beliefs and attitudes about sleep (DBAS): validation of a brief version (DBAS-16). Sleep 2007;30:1547-54. 67. Buysse DJ, Reynolds CF 3rd, Monk TH et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatr Res 1989;28:193-213. 68. Koffel EA, Koffel JB, Gehrman PR. A meta-analysis of group cognitive behavioral therapy for insomnia. Sleep Med Rev 2015;19:6-16. 69. van Straten A, van der Zweerde T, Kleiboer A et al. Cognitive and behavioral therapies in the treatment of insomnia: a meta-analysis. Sleep Med Rev 2018;38:3-16. 70. Wu JQ, Appleman ER, Salazar RD et al. Cognitive behavioral therapy for insomnia comorbid with psychiatric and medical conditions: a meta-analysis. JAMA Intern Med 2015;175:1461-72. 71. Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol 2006;25:3-14. 72. Smith MT, Perlis ML, Park A et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002;159:5-11. 73. Seyffert M, Lagisetty P, Landgraf J et al. Internet-delivered cognitive behavioral therapy to treat insomnia: a systematic review and meta-analysis. PLoS One 2016;11:e0149139. 74. Qaseem A, Kansagara D, Forciea MA et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American Col-lege of Physicians. Ann Intern Med 2016;165: 125-33. 75. Manber R, Carney C. Treatment plans and interventions for insomnia: a case formulation approach. New York: Guilford, 2015. 76. Edinger J, Carney C. Overcoming insomnia: a cognitive-behavioral therapy approach. Oxford: Oxford University Press, 2015. 77. Edinger JD, Wohlgemuth WK, Radtke RA et al. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA 2001;285:1856-64. 78. Haack M, Scott-Sutherland J, Santangelo G et al. Pain sensitivity and modulation in primary insomnia. Eur J Pain 2012;16:522-33. 79. Colombo C, Benedetti F, Barbini B et al. Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. Psy-chiatry Res 1999;86:267-70. 80. Trauer JM, Qian MY, Doyle JS et al. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med 163;191-204. 81. Geiger-Brown JM, Rogers VE, Liu W et al. Cognitive behavioral therapy in persons with comorbid insomnia: a meta-analysis. Sleep Med Rev 2015;23:54-67. 82. Ho FY, Chan CS, Tang KN. Cognitive-behavioral therapy for sleep disturbances in treating posttraumatic stress disorder symptoms: a meta-analy-sis of randomized controlled trials. Clin Psychol Rev 2016;43:90-102. 83. Belleville G, Cousineau H, Levrier K et al. Meta-analytic review of the impact of cognitive-behavior therapy for insomnia on concomitant anxiety. Clin Psychol Rev 2011;31:638-52. 84. Ye YY, Zhang YF, Chen J et al. Internet-based cognitive behavioral therapy for insomnia (ICBT-I) improves comorbid anxiety and depression – a me-ta-analysis of randomized controlled trials. PLoS One 2015;10:e0142258. 85. Espie CA, Emsley R, Kyle SD et al. Effect of digital cognitive behavioral therapy for insomnia on health, psychological well-being and sleep-related quality of life: a randomized clinical trial. JAMA Psychiatry 2019;76:21-30. 86. Krystal AD, Prather AA. Should internet cognitive behavioral therapy for insomnia be the primary treatment option for insomnia?: Toward getting more SHUTi. JAMA Psychiatry 2017;74:15-6. 87. Hajak G, Clarenbach P, Fischer W et al. Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol 1994;9:251-61. 88. Drake CL, Roehrs TA, Mangano RM et al. Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic pri-mary insomnia. Hum Psychopharmacol 2000;15:595-604. 89. Fabre LF Jr, Brachfeld J, Meyer LR et al. Multi-clinic double-blind comparison of triazolam (Halcion) and placebo administered for 14 consecutive nights in outpatients with insomnia. J Clin Psychiatry 1978;39:679-82. 90. Nair NP, Schwartz G, Dimitri R et al. A dose-range finding study of zopiclone in insomniac patients. Int Clin Psychopharmacol 1990;5(Suppl. 2):1-10. 91. Scharf MB, Roth PB, Dominguez RA et al. Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with in-somnia. J Clin Pharmacol 1990;30:461-7. 92. Walsh JK, Targum SD, Pegram V. A multi-center clinical investigation of estazolam: short-term efficacy. Curr Ther Res 1984;36:866-74. 93. Roehrs T, Zorick F, Lord N et al. Dose-related effects of estazolam on sleep of patients with insomnia. J Clin Psychopharmacol 1983;3:152-6. 94. Aden GC, Thatcher C. Quazepam in the short-term treatment of insomnia in outpatients. J Clin Psychiatry 1983;44:454-6. 95. Fillingim JM. Double-blind evaluation of the efficacy and safety of temazepam in outpatients with insomnia. Br J Clin Pharmacol 1979;8:73S-7. 96. Scharf MB, Roth T, Vogel GW et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-9. 97. Walsh JK, Erman M, Erwin CW et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharma-col 1998;13:191-8. 98. Elie R, Ruther E, Farr I et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry 1999;60:536-44. 99.Walsh JK, Roth T, Randazzo A et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000;23:1087-96. 100. Perlis ML, McCall WV, Krystal AD et al. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 2004;65:1128-37. 101. Roth T, Soubrane C, Titeux L et al. Zoladult Study Group. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7:397-406. 102. Krystal AD, Erman M, Zammit GK et al. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008;31:79-90. 103. Roth T, Krystal A, Steinberg FJ et al. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. Sleep 2013;36:189-96. 104. Walsh JK, Vogel GW, Scharf M et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000;1:41-9. 105. Ngen CC, Hassan R. A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia. Int Clin Psychopharmacol 1990;5:165-71. 106. Krystal AD, Walsh JK, Laska E et al. Sustained efficacy of eszopiclone over six months of nightly treatment: results of a randomized, double-blind, placebo controlled study in adults with chronic insomnia. Sleep 2003;26:793-9. 107. Walsh JK, Krystal AD, Amata DA et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007;30:959-68. 108. Zammit GK, McNabb LJ, Caron J et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979-91. 109. Erman M, Seiden D, Zammit G et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17-24. 110. Kohsaka M, Kanemura T, Taniguchi M et al. Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Jap-anese patients with chronic primary insomnia. Expert Rev Neurother 2011;11:1389-97. 111. Mayer G, Wang-Weigand S, Roth-Schechter B et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009;32:351-60. 112. Uchiyama M, Hamamura M, Kuwano T et al. Long-term safety and efficacyof ramelteon in Japanese patients with chronic insomnia. Sleep Med 2011;12:127-33. 113. Zammit G, Erman M, Wang-Weigand S et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3:495-504. 114. Roth T, Rogowski R, Hull S et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007;30:1555-61. 115. Hajak G, Rodenbeck A, Voderholzer U et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double blind, polysomnograph-ic study. J Clin Psychiatry 2001;62:453-63. 116. Lankford A, Rogowski R, Essink B et al. Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med 2012;13:133-8. 117. Krystal AD, Lankford A, Durrence HH et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic pri-mary insomnia. Sleep 2011;34:1433-42.118. Herring WJ, Connor KM, Ivgy-May N et al. Suvorexant in patients with in-somnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry 2016;79:136-48. 119. Herring WJ, Snyder E, Budd K et al. Orexin receptor antagonism for treat-ment of insomnia: a randomized clinical trial of suvorexant. Neurology 2012;79:2265-74. 120. Michelson D, Snyder E, Paradis E et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:461-71. 121. Elie R, Frenay M, Le Morvan P et al. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychophar-macol 1990;5(Suppl. 2):39-46. 122. Reeves RL. Comparison of triazolam, flurazepam, and placebo as hypnotics in geriatric patients with insomnia. J Clin Pharmacol 1977;17:319-23. 123. Piccione P, Zorick F, Lutz T et al. The efficacy of triazolam and chloral hydrate in geriatric insomniacs. J Int Med Res 1980;8:361-7. 124. Sunshine A. Comparison of the hypnotic activity of triazolam, flurazepam hydrochloride, and placebo. Clin Pharmacol Ther 1975;17:573-7. 125. Roehrs T, Zorick F, Wittig R et al. Efficacy of a reduced triazolam dose in elderly insomniacs. Neurobiol Aging 1985;6:293-6. 126. Morin CM, Colecchi C, Stone J et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281:991-9. 127. Ancoli-Israel S, Walsh JK, Mangano RM et al. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without caus-ing rebound effects. Prim Care Companion J Clin Psychiatry 1999;1:114-20. 128. Walsh JK, Soubrane C, Roth T. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry 2008;16:44-57. 129. Hedner J, Yaeche R, Emilien G et al. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with in-somnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psy-chiatry 2000;15:704-12. 130. Scharf M, Erman M, Rosenberg R et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005;28:720-7. 131. McCall WV, Erman M, Krystal AD et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006;22:1633-42. 132. Ancoli-Israel S, Krystal AD, McCall WV et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep 2010;33:225-34. 133. Roth T, Seiden D, Wang-Weigand S et al. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic in-somnia. Curr Med Res Opin 2007;23:1005-14. 134. Roth T, Seiden D, Sainati S et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006;7:312-8. 135. Scharf M, Rogowski R, Hull S et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008;69:1557-64. 136. Krystal AD, Durrence HH, Scharf M et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010;33:1553-61. 137. Herring WJ, Connor KM, Snyder E et al. Suvorexant in elderly patients with insomnia: pooled analyses of data from phase III randomized con-trolled clinical trials. Am J Geriatr Psychiatry 2017;25:791-802. 138. Downing SS, Lee YT, Farb DH et al. Benzodiazepine modulation of partial agonist efficacy and spontaneously active GABA receptors supports an al-losteric model of modulation. Br J Pharmacol 2005;145:894-906. 139. Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology. New York: McGraw-Hill Medical, 2009. 140. Sieghart W, Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes, Curr Top Med Chem 2002;2:795-816. 141. Krogsgaard-Larsen P, Frolund B, Liljefors T. Specific GABA(A) agonists and partial agonists. Chem Rec 2002;2:419-30. 142. Morin CM, Drake CL, Harvey AG et al. Insomnia disorder. Nat Rev Dis Primers 2015;1:15026 143. National Institutes of Health. Consensus conference. Drugs and insomnia. The use of medications to promote sleep. JAMA 1984;251:2410-4. 144. Krystal AD, McCall WV, Fava M et al. Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity. Prim Care Companion CNS Disord 2012;14(4). 145. Pollack MH, Hoge EA, Worthington JJ et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72:892-7. 146. Pollack M, Kinrys G, Krystal A et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxi-ety disorder. Arch Gen Psychiatry 2008;65:551-62. 147. Goforth HW, Preud’homme XA, Krystal AD. A randomized, double-blind, placebo-controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep 2014;37:1053-60. 148. Krystal A, Fava M, Rubens R et al. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depres-sion. J Clin Sleep Med 2007;3:48-55. 149. Fava M, McCall WV, Krystal A et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive dis-order. Biol Psychiatry 2006;59:1052-60. 150. Fava M, Asnis GM, Shrivastava RK et al. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem ex-tended-release 12.5 mg and escitalopram treatment: a randomized con-trolled trial. J Clin Psychiatry 2011;72:914-28. 151. Fava M, Asnis GM, Shrivastava R et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and general-ized anxiety disorder. J Clin Psychopharmacol 2009;29:222-30. 152. Ng KY, Leong MK, Liang H et al. Melatonin receptors: distribution in mammalian brain and their respective putative functions. Brain Struct Funct 2017;222:2921-39. 153. Krystal A. The possibility of preventing functional impairment due to sleep loss by pharmacologically enhancing sleep. Sleep 2005;28:16-7. 154. Slotten H, Krekling S. Does melatonin have an effect on cognitive performance. Psychoneuroendocrinology 1996;21:673-80. 155. Hughes R, Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep 1997;20:124-31. 156. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 2013;8:e63773. 157. Buscemi N, Vandermeer B, Hooton N et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005;20:1151-8. 158. Smits M, Nagtegaal EE, van der Heijden J et al. Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial. J Child Neurol 2001;16:86-92. 159. Zhdanova I, Wurtman RJ, Morabito C et al. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996;19:423-31. 160. Zhdanova I, Wurtman RJ, Wagstaff J. Effects of a low dose of melatonin on sleep in children with Angelman syndrome. J Pediatr Endocrinol 1999;12:57-67. 161. Van der Heijden K, Smits MG, Van Someren EJ et al. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insom-nia. J Am Acad Child Adolesc Psychiatry 2007;46: 233-41. 162. Wasdell M, Jan JE, Bomben MM et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syn-drome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 2008;44:57-64. 163. Braam W, Didden R, Smits M et al. Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study. J Intellect Disabil Res 2008;52:256-64. 164. Lerchl A. Melatonin administration alters semen quality in normal men. J Androl 2004;25:185-6. 165. Ianas O, Manda D, Câmpean D et al. Effects of melatonin and its relation to the hypothalamic-hypophyseal-gonadal axis. Adv Exp Med Biol 1999;460:321-8. 166. Partonen T. Melatonin-dependent infertility. Med Hypotheses 1999;52:269-70. 167. Pang SF, Li L, Ayre EA et al. Neuroendocrinology of melatonin in repro-duction: recent developments. J Chem Neuroanat 1998;14: 157-66. 168. Krystal AD, Richelson E, Roth T. Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications. Sleep Med Rev 2013;17:263-72. 169. Ruwe F, IJzerman-Boon P, Roth T et al. A phase 2 randomized dose-finding study with esmirtazapine in patients with primary insomnia. J Clin Psychopharmacol 2016;36:457-64. 170. Ivgy-May N, Ruwe F, Krystal A et al. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial. Sleep Med 2015;16:838-44. 171. Ivgy-May N, Roth T, Ruwe F et al. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week rand-omized outpatient trial. Sleep Med 2015;16:831-7. 172. Suppes T, Kelly DI, Perla JM et al. Challenges in the management of bipolar depression. J Clin Psychiatry 2005;66(Suppl. 5):11-6. 173. Chakravorty S, Hanlon AL, Kuna ST et al. The effects of quetiapine on sleep in recovering alcohol-dependent subjects: a pilot study. J Clin Psy-chopharmacol 2014;34:350-4. 174. Tassniyom K, Paholpak S, Tassniyom S et al. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai 2010;93:729-34. 175. Glass JR, Sproule BA, Herrmann N et al. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol 2008;28:182-8. 176. Morin CM, Koetter U, Bastien C et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005;28:1465-71. 177. Koppel C, Tenczer J, Ibe K. Poisoning with over-the-counter doxylamine preparations: an evaluation of 109 cases. Hum Toxicol 1987;6:355-9. 178. Rose M, Kam CA. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002;57:451-62. 179. Gajraj N. Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007;105:1805-15. 180. Furey SA, Hull SG, Leibowitz MT et al. A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gaba-pentin in transient insomnia induced by sleep phase advance. J Clin Sleep Med 2014;10:1101-9. 181. Rosenberg RP, Hull SG, Lankford DA et al. A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. J Clin Sleep Med 2014;10:1093-100. 182. Gilron I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. Curr Opin An-aesthesiol 2007;20:456-72. 183. de Haas S, Otte A, de Weerd A et al. Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy. J Clin Sleep Med 2007;3:473-8. 184. Garcia-Borreguero D, Larrosa O, de la Llave Y et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurol-ogy 2002;59:1573-9. 185. Holsboer-Trachsler E, Prieto R. Effects of pregabalin on sleep in generalized anxiety disorder. Int J Neuropsychopharmacol 2013;16:925-36. 186. Guay D. Pregabalin in neuropathic pain: a more “pharmaceutically elegant” gabapentin? Am J Geriatr Pharmacother 2005;3:274-87. 187. Brower K, Myra Kim H, Strobbe S et al. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and co-morbid insomnia. Alcohol Clin Exp Res 2008;32:1429-38. 188. Voris J, Smith NL, Rao SM et al. Gabapentin for the treatment of ethanol withdrawal. Subst Abus 2003;24:129-32.